Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

U.S. Medical Cannabis Market Size Worth USD 19.48 Billion By 2024: Hexa Research

Hexa Research
Posted on: 06 Sep 17
U.S. Medical Cannabis Market Size Worth USD 19.48 Billion By 2024: Hexa Research

PR Newswire

FELTON, California, September 6, 2017

FELTON, California, September 6, 2017 /PRNewswire/ --

The U.S. medical cannabismarket is expected to be valued at USD 19.48 billion by 2024, driven by its numerous medical benefits particularly by patients suffering from cancer, chronic pain and diabetes. Favorable regulatory environment across numerous states including California and Colorado is expected to fuel the growth of the market over the next few years.

Medical Marijuana Regulation and Safety Act implemented in 2015 permits the cultivation and use of cannabis dispensaries at the state and local level which has been one of key drivers to fuel the U.S market. The rising number of states receiving approval to utilize cannabis for consumption in medical cases is expected to be one of the crucial factors to upsurge the demand for medical marijuana over the forecast period.

Over the past few decades, there have been several controversies surrounding legalization of cannabis for medical purposes; however, increasing signs of medical benefits received from the consumption of cannabis has resulted in the herb being legalized across various states in the nation. The industry is expected to witness significant growth during the forecast period owing to greater consumer acceptance along with an increasing number of companies entering the market.

The symptoms and conditions that can be treated by the herb include cancer, arthritis, epilepsy, nausea, pain Alzheimer's disease, anorexia, AIDS, HIV, glaucoma, cachexia, Crohn's disease, migraines, and multiple sclerosis. Chronic pain accounted for 46% of the U.S. cannabis medical market share in 2016. The ability of medical marijuana to curb pain is expected to gain popularity among patients diagnosed with chronic illnesses and pain.

Browse full research report with TOC on " U.S. Medical Cannabis Market Size and Forecast, By Usage (Chronic Pain, Arthritis, Migraine, Cancer), By Consumption (Solid Edibles, Inhalation, Liquid Edibles, Topical), By State (California, Colorado, Washington, Arizona, Michigan), And Trend Analysis, 2014 - 2024 " at: e search-report/us-medical-cannabis-market

In 2016, solid edibles segment dominated the U.S market generating revenues worth USD 2.47 billion and is expected to continue dominating the industry over the forecast period. The future product innovation and potential growth are substantial owing to continuous development from the consumption of cannabis infused products owing to their numerous applications including lotions, bath salts, shampoo, lip balm, toothpaste, coffee pods, baked brownies cookies, candy, confectioneries, beverages, vinegar and oils.

California is known to be the first state in U.S. that legalized cannabis for medical purpose. In 2016, California recorded the highest revenue generation and is expected to grow at a CAGR of 13% over the projected period. Over the next few years, more number of state governments are expected to legalize cannabis owing to its numerous benefits which will fuel its growth over the projected period.

Browse reports of similar category by Hexa Research: 

  • Teeth Whitening Produ c ts Market - Global teeth whitening products market was valued at USD 5.56 billion in 2016. The rising demand for over-the-counter bleaching products coupled with increasing focus on appearance and role of white teeth in personality building are expected to upsurge the growth during the forecast period.
  • Biosimilars Ma r ket - Global biosimilars market size was valued at 3.39 billion in 2016 and is expected to grow on account of increasing prevalence of chronic diseases such as cancer and autoimmune disorders.
  • Ultracentrifu g es Market - Global ultracentrifuges market size was estimated to be worth USD 27.8 million in 2016. An increasing number of diseases has resulted in an increased utilization of ultracentrifuge for the development of vaccines.
  • Glioblastoma Multif o rme Market - Global glioblastoma multiforme (GBM) market was estimated to be USD 464.8 million in 2016 and is expected to grow significantly over the forecast period primarily due to the rising ageing population

Hexa Research has segmented the U.S. medical cannabis market based on usage, consumption and state: 

Segmentation by usage, 2014 - 2024 (USD Million) 

• Chronic Pain

• Arthritis

• Migraine

• Cancer

• Others

Segmentation by consumption, 2014 - 2024 (USD Million) 

• Solid Edibles

• Inhalation

• Liquid Edibles

• Topical

Segmentation by state, 2014 - 2024 (USD Million) 

• California

• Colorado

• Washington

• Arizona

• Michigan

Key players analyzed 

• American Cannabis

• Canopy Growth Corporation

• Greengro Technologies

• Medical Marijuana Inc.

• United Cannabis

• Terra Tech Corp.

• Mentor Capital, Inc

• Cannabis Sativa, Inc.

• GBSciences, Inc.

• The Green Solution

About Hexa Research 

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Michelle T.
Corporate Sales Specialist
Hexa Research
Phone: +1-415-349-0058
Toll Free: 1-800-489-3075


SOURCE Hexa Research

PR Newswire

Last updated on: 06/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.